Four phase 3 trials of intravenous t-PA for ischaemic stroke have been reported. The FDA of North America approved this therapy on the basis of the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study (NINDS rt-PA Stroke Study). Other large trials have been less favourable including ECASS I, ECASS II and ATLANTIS.
Three trials of streptokinase have been initiated but halted because of excess mortality and poor outcome.
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.